Omeros (NASDAQ:OMER) Downgraded to Sell Rating by StockNews.com

StockNews.com downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research report released on Friday.

OMER has been the subject of a number of other research reports. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

OMER stock opened at $9.10 on Friday. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60. The firm has a market capitalization of $527.35 million, a P/E ratio of -3.94 and a beta of 2.03. The firm has a 50 day moving average of $8.70 and a 200-day moving average of $7.32.

Institutional Investors Weigh In On Omeros

Institutional investors have recently made changes to their positions in the business. Barclays PLC boosted its stake in shares of Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 51,873 shares in the last quarter. State Street Corp boosted its stake in shares of Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after purchasing an additional 3,839 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Omeros by 7.2% in the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 4,000 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Omeros in the 3rd quarter valued at $305,000. Finally, MML Investors Services LLC boosted its stake in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.